– USA, CA – 4D Molecular Therapeutics, a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, today announced the appointment of Nancy Miller-Rich and Shawn Tomasello to its Board of Directors.
“We are thrilled to welcome both Nancy and Shawn to our Board of Directors as we embark on the next phase of our evolution,” said co-founder and CEO, Dr. David Kirn. “Both appointments reflect our commitment to build a fully-integrated biopharmaceutical company. We look forward to benefiting from Nancy and Shawn’s extensive commercialization experience as we advance 4DMT’s next-generation gene therapy programs.”
Nancy Miller-Rich brings 35 years of experience in the healthcare industry, with significant expertise in business development and commercial strategy.
Shawn Tomasello brings over 30 years of experience in the life sciences industry, with significant expertise in building and leading commercial organizations.
About Nancy Miller-Rich
Ms. Miller-Rich has served in several leadership roles at Merck and, before the merger of the two companies, at Schering-Plough. She was most recently SVP, Global Human Health Business Development & Licensing, Strategy and Commercial Support and before that Group VP, Consumer Care, Global New Ventures, and Strategic Commercial Development.
Ms. Miller-Rich currently serves on the Board of Directors of Aldeyra Therapeutics as well as several private and not-for-profit entities.
She received her B.S. in Business Administration, Marketing from Ithaca College in Ithaca, New York.
About Shawn Tomasello
Ms. Tomasello most recently served as Chief Commercial Officer of Kite Pharma, where she led the commercialization of Yescarta, the first approved CAR-T therapy for the treatment of adult patients with relapsed or refractory non-Hodgkin lymphoma. Before joining Kite, she served as Chief Commercial Officer at Pharmacyclics, Inc., during which time the brand Imbruvica was awarded the prestigious 2015 Prix Galien Award for Best Pharmaceutical Agent. Previously, she held senior leadership positions at Celgene Corporation, including President of the Americas, Hematology, and Oncology. During her tenure at Celgene, Ms. Tomasello was responsible for all aspects of commercial sales and marketing for five brands encompassing 11 indications. Before this, she was National Director of Hematology for Rituxan at Genentech, representing the most significant portion of the company’s product revenue during her tenure.
Ms. Tomasello currently serves on the Board of Directors of the following publicly-held companies: Urogen Pharma, Gamida Cell, and Mesoblast.
Ms. Tomasello holds a B.S. degree in marketing from the University of Cincinnati and an M.B.A. from Murray State University, KY.
4DMT is a clinical-stage gene therapy company pioneering the development of product candidates using targeted and evolved AAV vectors. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products. The company is initially focused on three therapeutic areas: ophthalmology, cardiology, and pulmonology. The 4DMT targeted and evolved vectors are invented to be delivered through clinically routine, well-tolerated, and minimally invasive routes of administration, transducing diseased cells in target tissues efficiently, having reduced immunogenicity, and, where relevant, having resistance to pre-existing antibodies. 4DMT is currently conducting three clinical trials: 4D-125 is in a Phase 1/2 clinical trial for XLRP, 4D-110 is in Phase 1 clinical trial for choroideremia and 4D-310 is in a Phase 1/2 clinical trial for Fabry disease.
For more information: https://www.4dmoleculartherapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.